In The News: Department of Brain Health
Over the past year, the field has experienced another significant leap of growth, powered by advances in translational research and capped off by the approval of lecanemab (Leqembi; Eisai), the first traditionally approved therapy in nearly two decades.
After decades of failed trials, ineffective drugs and billions of dollars spent, a new frontier of shots offer a glimmer of hope for current and future sufferers of the cruel condition that affects 5.8million Americans.
The positive results are expected to form the basis for further development of Lomecel-B as a potential treatment for mild AD
Longeveron, a clinical-stage biotechnology company developing cellular therapies for aging-related and life-threatening conditions, reported positive top-line results from its CLEAR MIND Phase 2a human clinical trial
Neurologists at the biggest Alzheimer's research meeting in the US experienced something this week they hadn't in years: optimism.
Neurologists at the biggest Alzheimer鈥檚 research meeting in the US experienced something this week they hadn鈥檛 in years: optimism.
In 2014 neurologist Jeffrey L. Cummings, MD, startled the Alzheimer鈥檚 disease research world with a paper that laid bare the alarmingly high failure rate of Alzheimer鈥檚 disease therapies in development.
The FDA was busy in September 2023, making a number of decisions on potential new therapeutic agents including granting approvals, updating a label, issuing complete response letters, granting a clearance, and lifting a clinical trial hold, among other actions.
Longeveron Inc. (NASDAQ: LGVN) (鈥淟ongeveron鈥 or 鈥淐ompany鈥), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (HLHS), Alzheimer鈥檚 disease and Aging-related Frailty, today announced positive top-line results from its Phase 2a trial of its investigational product Lomecel-B鈩 for the treatment of mild Alzheimer鈥檚 disease.
The Miami company is developing treatments for aging-related chronic diseases.
Top-line Phase IIa data has demonstrated an allogeneic stem-cell therapy facilitated a lack of deterioration in cognitive signals in mild Alzheimer鈥檚.
As a neurologist with more than 30 years in the field of Alzheimer鈥檚 disease, I have had many heartbreaking conversations with patients and their loved ones. More than 6 million people in America are living with Alzheimer鈥檚 disease, and that staggering number is expected to double within the next 30 years unless there is a change. However, I am more optimistic about that change and physicians鈥 ability to slow the course of this devastating illness than I have ever been in the past.